Abstract:Abstract Background Multiple sclerosis (MS) is one of the most common autoimmune disorders characterized by the infiltration of immune cells into the brain and demyelination. The unwanted immunosuppressive side effect of therapeutically successful natalizumab led us to focus on the choroid plexus (CP), a key site for the first wave of immune cell infiltration in experimental autoimmune encephalomyelitis (EAE), for the control of immune cells trafficking. Adenosine A 2A receptor (A 2A R) is emerging as a potential pharmacological target to control EAE pathogenesis. However, the cellular basis for the A 2A R-mediated protection remains undetermined. Methods In the EAE model, we assessed A 2A R expression and leukocyte trafficking determinants in the CP by immunohistochemistry and qPCR analyses. We determined the effect of the A 2A R antagonist KW6002 treatment at days 8–12 or 8–14 post-immunization on T cell infiltration across the CP and EAE pathology. We determined the critical role of the CP-A 2A R on T cell infiltration and EAE pathology by focal knock-down of CP-A 2A R via intracerebroventricular injection of CRE-TAT recombinase into the A 2A R flox/flox mice. In the cultured CP epithelium, we also evaluated the effect of overexpression of A 2A Rs or the A 2A R agonist CGS21680 treatment on the CP permeability and lymphocytes migration. Results We found the specific upregulation of A 2A R in the CP associated with enhanced CP gateway activity peaked at day 12 post-immunization in EAE mice. Furthermore, the KW6002 treatment at days 8–12 or 8–14 post-immunization reduced T cell trafficking across the CP and attenuated EAE pathology. Importantly, focal CP-A 2A R knock-down attenuated the pathogenic infiltration of Th17 + cells across the CP via inhibiting the CCR6–CCL20 axis through NFκB/STAT3 pathway and protected against EAE pathology. Lastly, activation of A 2A R in the cultured epithelium by A 2A R overexpression or CGS21680 treatment increased the permeability of the CP epithelium and facilitated lymphocytes migration. Conclusion These findings define the CP niche as one of the primary sites of A 2A R action, whereby A 2A R antagonists confer protection against EAE pathology. Thus, pharmacological targeting of the CP-A 2A R represents a novel therapeutic strategy for MS by controlling immune cell trafficking across CP.

The Adenosine A2A Receptor Antagonist SCH58261 Reduces Macrophage/microglia Activation and Protects Against Experimental Autoimmune Encephalomyelitis in Mice.

Blocking A(2b) Adenosine Receptor Alleviates Pathogenesis of Experimental Autoimmune Encephalomyelitis Via Inhibition of Il-6 Production and Th17 Differentiation

A2AR antagonist treatment for multiple sclerosis: Current progress and future prospects

Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Activation of the Adenosine A2A Receptor Attenuates Experimental Autoimmune Myasthenia Gravis Severity.

Activation of A2B Adenosine Receptor Protects Against Demyelination in a Mouse Model of Schizophrenia

Adenosine A2A Receptor Antagonist SCH58261 Improves the Cognitive Function in Alzheimer’s Disease Model Mice Through Activation of Nrf2 Via an Autophagy-Dependent Pathway

9,10-Anhydrodehydroartemisinin Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Th1 and Th17 Cell Differentiation

High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis

Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels.

Matrine Alleviates Astrogliosis Through Sphingosine 1-Phosphate Signaling in Experimental Autoimmune Encephalomyelitis

Role of C16, angiopoietin-1 and regeneration gene protein 2 in attenuating inflammation in an experimental rat model of autoimmune encephalomyelitis.

Treatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathways

Adoptive Transfer Of Immunomodulatory M2 Macrophages Suppresses Experimental Autoimmune Encephalomyelitis In C57bl/6 Mice Via Blockading Nf-Kappa B Pathway

Spermidine alleviates experimental autoimmune encephalomyelitis through inducing inhibitory macrophages

The adenosine A (2A) receptor antagonist SCH58261 protects photoreceptors by inhibiting microglial activation and the inflammatory response

Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer’s Disease Mouse Models: A Potential Role for Aβ

Blocking Initial Infiltration of Pioneer Cd8(+) T-Cells into the Cns Via Inhibition of Shp-2 Ameliorates Experimental Autoimmune Encephalomyelitis in Mice

Immunoregulation of Experimental Autoimmune Encephalomyelitis by the Selective CB1 Receptor Antagonist.